155 related articles for article (PubMed ID: 37784253)
21. Chordoma: Immunohistochemical Analysis of Brachury.
Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
[TBL] [Abstract][Full Text] [Related]
22. Intradural chordoma presenting with intratumoral bleeding.
Vellutini Ede A; de Oliveira MF
J Clin Neurosci; 2016 Mar; 25():139-42. PubMed ID: 26563604
[TBL] [Abstract][Full Text] [Related]
23. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
24. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
25. Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence.
Deniz ML; Kiliç T; Almaata I; Kurtkaya O; Sav A; Pamir MN
Neurosurgery; 2002 Sep; 51(3):753-60; discussion 760. PubMed ID: 12188955
[TBL] [Abstract][Full Text] [Related]
26. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor (EGFR) status in chordoma.
Ptaszyński K; Szumera-Ciećkiewicz A; Owczarek J; Mrozkowiak A; Pekul M; Barańska J; Rutkowski P
Pol J Pathol; 2009; 60(2):81-7. PubMed ID: 19886182
[TBL] [Abstract][Full Text] [Related]
28. Loss of H3K27 trimethylation in a distinct group of de-differentiated chordoma of the skull base.
Makise N; Shimoi T; Sunami K; Aoyagi Y; Kobayashi H; Tanaka S; Kawai A; Yonemori K; Ushiku T; Yoshida A
Histopathology; 2023 Feb; 82(3):420-430. PubMed ID: 36217885
[TBL] [Abstract][Full Text] [Related]
29. Molecular features and vulnerabilities of recurrent chordomas.
Seeling C; Lechel A; Svinarenko M; Möller P; Barth TFE; Mellert K
J Exp Clin Cancer Res; 2021 Jul; 40(1):244. PubMed ID: 34330313
[TBL] [Abstract][Full Text] [Related]
30. Multimodal profiling of chordoma immunity reveals distinct immune contextures.
van Oost S; Meijer DM; Ijsselsteijn ME; Roelands JP; van den Akker BEMW; van der Breggen R; Briaire-de Bruijn IH; van der Ploeg M; Wijers-Koster PM; Polak SB; Peul WC; van der Wal RJP; de Miranda NFCC; Bovee JVMG
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272563
[TBL] [Abstract][Full Text] [Related]
31. Surgical Management of Skull Base and Spine Chordomas.
Passer JZ; Alvarez-Breckenridge C; Rhines L; DeMonte F; Tatsui C; Raza SM
Curr Treat Options Oncol; 2021 Mar; 22(5):40. PubMed ID: 33743089
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.
Bai J; Zhai Y; Wang S; Gao H; Du J; Wang J; Li M; Li C; Gui S; Zhang C; Sun Y; Zhang Y
World Neurosurg; 2017 Mar; 99():282-287. PubMed ID: 27916725
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1.
Scheil S; Brüderlein S; Liehr T; Starke H; Herms J; Schulte M; Möller P
Genes Chromosomes Cancer; 2001 Nov; 32(3):203-11. PubMed ID: 11579460
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological implications of TIM3
Zhou J; Jiang Y; Zhang H; Chen L; Luo P; Li L; Zhao J; Lv F; Zou D; Zhang Y; Jing Z
Cancer Immunol Immunother; 2019 Jul; 68(7):1157-1169. PubMed ID: 31197461
[TBL] [Abstract][Full Text] [Related]
35. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
[TBL] [Abstract][Full Text] [Related]
36. Clinical findings in families with chordoma with and without T gene duplications and in patients with sporadic chordoma reported to the Surveillance, Epidemiology, and End Results program.
Parry DM; McMaster ML; Liebsch NJ; Patronas NJ; Quezado MM; Zametkin D; Yang XR; Goldstein AM
J Neurosurg; 2020 Jun; 134(5):1399-1408. PubMed ID: 32559743
[TBL] [Abstract][Full Text] [Related]
37. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability.
Naka T; Boltze C; Samii A; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
Cancer; 2003 Nov; 98(9):1934-41. PubMed ID: 14584077
[TBL] [Abstract][Full Text] [Related]
38. First cytogenetic study of a recurrent familial chordoma of the clivus.
Dalprà L; Malgara R; Miozzo M; Riva P; Volonte M; Larizza L; Fuhrman Conti AM
Int J Cancer; 1999 Mar; 81(1):24-30. PubMed ID: 10077147
[TBL] [Abstract][Full Text] [Related]
39. Genomic aberrations frequently alter chromatin regulatory genes in chordoma.
Wang L; Zehir A; Nafa K; Zhou N; Berger MF; Casanova J; Sadowska J; Lu C; Allis CD; Gounder M; Chandhanayingyong C; Ladanyi M; Boland PJ; Hameed M
Genes Chromosomes Cancer; 2016 Jul; 55(7):591-600. PubMed ID: 27072194
[TBL] [Abstract][Full Text] [Related]
40. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases.
Hoch BL; Nielsen GP; Liebsch NJ; Rosenberg AE
Am J Surg Pathol; 2006 Jul; 30(7):811-8. PubMed ID: 16819322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
